SCHEMBL6605096

SCHEMBL6605096

C[C](N)C1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27394165 0.83
SCHEMBL4244197 0.77 NOS2 (0.43)
SCHEMBL9978895 0.73 CES2 (0.47)
SCHEMBL9051813 0.73 NOS2 (0.53)
SCHEMBL6265136 0.73 CES2 (0.47)
SCHEMBL5131 0.73 CES2 (0.47)
SCHEMBL5281 0.73
SCHEMBL1858120 0.73 CES2 (0.47)
SCHEMBL673560 0.73 CES2 (0.47)
SCHEMBL5411 0.73 CES2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174509-A1 THERAPEUTIC USE OF PLEUROMUTILINS ARIVA MED GMBH (AT) 2023-06-08 US claimed
EP-4135683-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GMBH (AT) 2023-02-22 EP claimed
CN-115413238-A Therapeutic use of pleuromutilin compounds 纳布里瓦治疗有限责任公司 2022-11-29 CN claimed
WO-2021209596-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-10-21 WO claimed
EP-3096751-B1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-01-06 EP claimed
CN-105916499-B 12-epi-pleuromutilins 纳布里瓦治疗股份公司 2020-02-18 CN claimed
WO-2017189866-A1 POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS SPERO OPCO (US) 2017-11-02 WO claimed
US-9701628-B2 12-epi pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2017-07-11 US claimed
EP-3096751-A1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics AG (AT) 2016-11-30 EP claimed
US-20160332963-A1 12-EPI PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2016-11-17 US claimed
WO-2015110481-A1 12-EPI-PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2015-07-30 WO claimed
CN-100396668-C Non-imidazole aryloxypiperidines ORTHO MCNEIL PHARM INC (US) 2008-06-25 CN claimed
US-20240208989-A1 NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF ARIVA MED GMBH (AT) 2024-06-27 US disclosed
EP-4323366-A1 NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF Nabriva Therapeutics GMBH (AT) 2024-02-21 EP disclosed
CN-117500809-A Novel 12-epimeric-mollin compounds and uses thereof 纳布里瓦治疗有限责任公司 2024-02-02 CN disclosed
US-20230250047-A1 METHOD FOR ISOMERIZING ALIPHATIC DIAMINE, METHOD FOR PRODUCING DIISOCYANATE, METHOD FOR PRODUCING POLYURETHANE, AND POLYURETHANE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-08-10 US disclosed
EP-1106614-A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP disclosed
CN-1048243-C Alkylation method of triazine derivative NISSAN CHEMICAL IND LTD (JP) 2000-01-12 CN disclosed
CN-1147812-A Alkylation method of triazine derivative NISSAN CHEMICAL IND LTD (JP) 1997-04-16 CN disclosed
CN-1127506-A Method of alkylating triazine derivative NISSAN CHEMICAL IND LTD (JP) 1996-07-24 CN disclosed